(Abstracted from Menopause 2018;25(8):862–869)
Approximately 70% of postmenopausal women experience vasomotor symptoms, and 10% describe these symptoms as intolerable. Conventional treatment of hot flashes (HFs) includes hormone therapy and other alternative treatments; however, these treatments have mixed responses, variable availability, and can be contraindicated in some women such as those with a history of breast cancer.
Department of Investigative Medicine, Imperial College London, London, United Kingdom (J.K.P., R.E.R., A.N.C., S.C., C.N.J., W.S.D.); Millendo Therapeutics, Inc, Ann Arbor (P.M., V.H.L.); TPS Pharmaceutical Consulting, Saline (T.P.S.), MI; Department of Gynaecology, Queen Charlotte's & Chelsea Hospital and Chelsea & Westminster Hospital (N.P.); Institute of Reproductive and Development Biology, Imperial College London (N.P.); Institute of Psychiatry, Psychology & Neuroscience, King's College London (M.S.H.), London; and Emerging Innovations Unit, Scientific Partnering and Alliances, IMED Biotech Unit, AstraZeneca, Cambridge (L.C.W.), United Kingdom